Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#OBJECT> ?p ?o ?g. }
- OBJECT label "outcome" assertion.
- OBJECT label "outcome" assertion.
- OBJECT label "outcome" assertion.
- OBJECT label "outcome" assertion.
- OBJECT label "a randomized , controlled , open - label multicenter trial among COVID-19 patients" assertion.
- OBJECT label "a randomized , controlled , open - label multicenter trial among COVID-19 patients" assertion.
- OBJECT label "a randomized , controlled , open - label multicenter trial among COVID-19 patients" assertion.
- OBJECT label "a randomized , controlled , open - label multicenter trial among COVID-19 patients" assertion.
- OBJECT label "a randomized , controlled , open - label multicenter trial among COVID-19 patients" assertion.
- OBJECT label "a randomized , controlled , open - label multicenter trial among COVID-19 patients" assertion.
- OBJECT label "an increase of inhaled oxygen concentration" assertion.
- OBJECT label "an increase of inhaled oxygen concentration" assertion.
- OBJECT label "an increase of inhaled oxygen concentration" assertion.
- OBJECT label "an increase of inhaled oxygen concentration" assertion.
- OBJECT label "an increase of inhaled oxygen concentration" assertion.
- OBJECT label "an increase of inhaled oxygen concentration" assertion.
- OBJECT label "an increase of inhaled oxygen concentration" assertion.
- OBJECT label "In moderate disease patients with bilateral pulmonary lesions" assertion.
- OBJECT label "In moderate disease patients with bilateral pulmonary lesions" assertion.
- OBJECT label "In moderate disease patients with bilateral pulmonary lesions" assertion.
- OBJECT label "In moderate disease patients with bilateral pulmonary lesions" assertion.
- OBJECT label "In moderate disease patients with bilateral pulmonary lesions" assertion.
- OBJECT label "In moderate disease patients with bilateral pulmonary lesions" assertion.
- OBJECT label "In moderate disease patients with bilateral pulmonary lesions" assertion.
- OBJECT label "higher than that" assertion.
- OBJECT label "higher than that" assertion.
- OBJECT label "higher than that" assertion.
- OBJECT label "higher than that" assertion.
- OBJECT label "higher than that" assertion.
- OBJECT label "higher than that" assertion.
- OBJECT label "higher than that" assertion.
- OBJECT label "in a 1:1 ratio to receive either Tocilizumab in addition to standard care or standard care alone" assertion.
- OBJECT label "in a 1:1 ratio to receive either Tocilizumab in addition to standard care or standard care alone" assertion.
- OBJECT label "in a 1:1 ratio to receive either Tocilizumab in addition to standard care or standard care alone" assertion.
- OBJECT label "in a 1:1 ratio to receive either Tocilizumab in addition to standard care or standard care alone" assertion.
- OBJECT label "in a 1:1 ratio to receive either Tocilizumab in addition to standard care or standard care alone" assertion.
- OBJECT label "in a 1:1 ratio to receive either Tocilizumab in addition to standard care or standard care alone" assertion.
- OBJECT label "in tocilizumab recipients 20/34 , 58.82 % than the controls 4/31 , 12.90 % " assertion.
- OBJECT label "in tocilizumab recipients 20/34 , 58.82 % than the controls 4/31 , 12.90 % " assertion.
- OBJECT label "in tocilizumab recipients 20/34 , 58.82 % than the controls 4/31 , 12.90 % " assertion.
- OBJECT label "in tocilizumab recipients 20/34 , 58.82 % than the controls 4/31 , 12.90 % " assertion.
- OBJECT label "in tocilizumab recipients 20/34 , 58.82 % than the controls 4/31 , 12.90 % " assertion.
- OBJECT label "in tocilizumab recipients 20/34 , 58.82 % than the controls 4/31 , 12.90 % " assertion.
- OBJECT label "to verify the effectiveness and safety of tocilizumab therapy in COVID 19 and identify patients most likely to benefit from tocilizumab therapy" assertion.
- OBJECT label "statistically significant 94 12 vs 87 10 " assertion.
- OBJECT label "the effectiveness and safety of tocilizumab therapy in COVID 19" assertion.
- OBJECT label "a randomized controlled open label multicenter trial among COVID 19 patients" assertion.
- OBJECT label "in a 1 1 ratio to receive either Tocilizumab in addition to standard care or standard care alone" assertion.
- OBJECT label "in tocilizumab recipients 20 34 58 82 than the controls 4 31 12 90 " assertion.
- OBJECT label "to attenuate the cytokine storm in COVID 19 patients" assertion.
- OBJECT label "higher from day 4 onward and statistically significant from day 12 P 0 0359 " assertion.
- OBJECT label "in addition to standard care or standard care alone" assertion.
- OBJECT label "accessible for authorized users" assertion.
- OBJECT label "hypoxia" assertion.
- OBJECT label "to the tocilizumab group" assertion.
- OBJECT label "randomized to the tocilizumab group" assertion.
- OBJECT label "the cytokine storm " assertion.
- OBJECT label "with the controls 4 6" assertion.
- OBJECT label "from tocilizumab therapy" assertion.
- OBJECT label "positive for serum HBV DNA 2 5 107 IU mL after 18 months of tocilizumab treatment 1 6 1 64 " assertion.
- OBJECT label "no HBV reactivation" assertion.
- OBJECT label "HBV reactivation" assertion.
- OBJECT label "HBV reactivation" assertion.
- OBJECT label "to be considered" assertion.
- OBJECT label "HBsAg HBcAb 26 8 " assertion.
- OBJECT label "HBsAg HBcAb 65 9 " assertion.
- OBJECT label "necessary" assertion.
- OBJECT label "the risk of hepatitis B virus reactivation in patients undergoing long term tocilizumab therapy for rheumatoid arthritis" assertion.
- OBJECT label "long term tocilizumab therapy for rheumatoid arthritis" assertion.
- OBJECT label "a high risk of HBV reactivation which could be prevented by antiviral prophylaxis" assertion.
- OBJECT label "with entecavir" assertion.
- OBJECT label "in 2 of the remaining 3 patients" assertion.
- OBJECT label "low in HBsAg HBcAb patients" assertion.
- OBJECT label "in this retrospective study" assertion.
- OBJECT label "HBV reactivation and hepatitis flare up" assertion.
- OBJECT label "antiviral prophylaxis" assertion.
- OBJECT label "antiviral prophylaxis" assertion.
- OBJECT label "the potential to reduce the mortality rate among severe COVID 19 patients" assertion.
- OBJECT label "the mortality rate among severe COVID 19 patients" assertion.
- OBJECT label "in treating rheumatoid arthritis" assertion.
- OBJECT label "9 years" assertion.
- OBJECT label "supplementary material which is available to authorized users" assertion.
- OBJECT label "available to authorized users" assertion.
- OBJECT label "HBsAg 7 2 " assertion.
- OBJECT label "a favorable outcome" assertion.
- OBJECT label "for a median of 29 months" assertion.
- OBJECT label "reduced glycocalyx thickness bpulse wave velocityPWV cglobal LV longitudinal strainGLS dglobal work indexGWI using speckle tracking echocardiography and eC reactive proteinCRP malondialdehydeMDA and protein carbonylsPCs as oxidative stress markers at baseline and post treatment" assertion.
- OBJECT label "speckle tracking echocardiography and eC reactive proteinCRP malondialdehydeMDA and protein carbonylsPCs as oxidative stress markers at baseline and post treatment" assertion.
- OBJECT label "endothelial function leading to a greater increase of effective myocardial work than csDMARDs GC through a profound reduction of inflammatory burden and oxidative stress" assertion.
- OBJECT label "the effects of tocilizumab on endothelial glycocalyx a determinant of vascular permeability" assertion.
- OBJECT label "antirheumatic drugscsDMARDs and glucocorticoidsGC " assertion.
- OBJECT label "to a greater increase of effective myocardial work than csDMARDs GC through a profound reduction of inflammatory burden and oxidative stress" assertion.
- OBJECT label "for 3 months" assertion.
- OBJECT label "with the percent decrease of PWV MDA PCs and the percent improvement of GLS and GWIP 0 05 " assertion.
- OBJECT label "randomized to" assertion.
- OBJECT label "impaired glycocalyx and myocardial deformation markersP 0 05 " assertion.
- OBJECT label "glycocalyx and myocardial deformation markersP 0 05 " assertion.
- OBJECT label "a greater increase of GLS GWI and reduction of MDA PCs and CRPP 0 05 " assertion.
- OBJECT label "indexGWI " assertion.
- OBJECT label "PBR2 14 0 2 versus" assertion.